AlphaLogix announces market release of AlphaFlo® canine allograft

4

Back to all posts

Press Release

AlphaLogix announces market release of AlphaFlo^® canine allograft

Equus Innovations, a manufacturer of advanced, next-generation veterinary regenerative products, in partnership with AlphaLogix, LLC (Argyle, Texas) announced today successful market release of a new canine allograft, AlphaFlo^®.

Read the Press Release

You may want to read these articles

RenoVō® vs. Alpha2EQ®: Comparing Equine Regenerative Options for Veterinary Use

As equine regenerative therapy evolves, veterinarians have more tools available to support tissue health. Two such products, RenoVō® and Alpha2EQ®, offer distinct biological compositions and clinical utility. Understanding their differences helps equine practitioners...

RenoVō^® Case Study: Inner Ear Squamous Cell Carcinoma

Case presentation: On November 3, 2022, a 13 year-old Gelding Grade Horse presented to Topgun Veterinarian Service, Rock Hill, SC, with a mass in the right inner ear. The attending veterinarian, Dr. Audrey Turbeville, performed an excisional biopsy for pathology and...

Cryopreserved Liquid Amnion Product vs. Powder (Lyophilized) Amnion Product

Amniotic tissue contains naturally occurring elements such as growth factors, cytokines, extracellular matrix proteins, and exosomes. These components are intrinsic to the native structure of the amniotic membrane and fluid and may be beneficial in supporting tissue...

Back to all posts

RenoVō® vs. Alpha2EQ®: Comparing Equine Regenerative Options for Veterinary Use

RenoVō® Case Study: Inner Ear Squamous Cell Carcinoma

Cryopreserved Liquid Amnion Product vs. Powder (Lyophilized) Amnion Product

RenoVō^® Case Study: Inner Ear Squamous Cell Carcinoma